Highlights form the Tenth Annual Scientific Meeting of the American
Society of Hypertension will be made available via the ASH-EHLB mail list.
To subscribe and receive information about this meeting, highlights
delivered to your email address during the meeting and a chance to
communicate with presenters, send a subscribe message (SUBSCRIBE

SUBSCRIBE John Doe

Meanwhile, here is the schedule pf sessions for:

THURSDAY, MAY 18
================

8:30 AM to 10:25 AM PLENARY SESSION I
-------------------------------------
   President's Welcome
   Richard Bright Award Lecture*
      Colin I. Johnston, MD, Heidelberg, Australia
PRESIDENT'S SYMPOSIUM: THE PATHOBIOLOGY OF ATHEROSCLEROSIS
   Cell Biology of Atherosclerosis
      Alan M. Fogelman, MD, Los Angeles, CA
   Modification of LDL Structure in Relation to Atherosclerosis
      Daniel Steinberg, MD, PhD, La Jolla, CA
   Cytokines, Inflammatory Mediators and Atherosclerosis
      R. Wayne Alexander, MD, PhD, Atlanta, GA

*This award is supported through an educational grant from Merck US Human
Health and Merck Research Laboratories.

10:45 AM to 12:30 PM
--------------------
Theme I: Molecular Biology and Genetics
      ACE Variants in Cardiovascular Disease
         To Be Announced
      Original Communications
Theme II: CNS Mechanisms in Hypertension
      The Imidazoline Receptor and Its Endogenous Ligands:
      Relationship to Pharmacology of Hypertension
         Donald J. Reis, MD, New York, NY
      Original Communications
Theme III: Social and Environmental Factors in Hypertension
      The Role of Socioeconomic Status in Hypertension
         Herman A. Tyroler, MD, Chapel Hill, NC
      Original Communications

1:30 PM to 3:30 PM
------------------
Theme I: NEURAL MECHANISMS IN HYPERTENSION
      Natriuretic Peptides in Brain: Role in {*filter*} Pressure
         Suzanne Oparil, MD, Birmingham, AL
      Nitric Oxide Dependent Neural Influences on {*filter*} Pressure
         David F. Bohr, MD, Ann Arbor, MI
      Antisense Inhibition of Hypertension:  A New Strategy for
      Renin-Angiotensin Candidate Genes
         M. Ian Phillips, PhD, DSc, Gainesville, FL
      Neural Mechanisms in Renal Parenchymal Hypertension
         Ronald G. Victor, MD, Dallas, TX
      Stress, Salt and Hypertension
         Gerald F. DiBona, MD, Iowa City, IA
      Discussion
Theme II: METABOLIC ISSUES AND TREATMENT OF HYPERTENSION**
      DEBATE: Should Lipid Lowering {*filter*} Play a Major Role
      in the Treatment of the Hypertensive Patient?
         Pro: John C. LaRosa, MD, New Orleans, LA
         Con: Lawrence E. Ramsay, MD, Sheffield, England
      Discussion
      Mechanism of Insulin Resistance and Hypertension
         Alain D. Baron, MD, Indianapolis, IN
      Therapeutic Implications of Insulin Resistance in
      Hypertension
         Willa Hsueh, MD, Los Angeles, CA
      Discussion

**Supported by an educational grant from Bristol-Myers Squibb Company.

Theme III: SOCIOECONOMIC DETERMINANTS OF HYPERTENSION
      AND ITS CONTROL
      NHANES III Data
         Vicki L. Burt, ScM, RN, National Center for Health
         Statistics, Hyattsville, MD
      Stress and Hypertension
         Thomas G. Pickering, MD, PhD, New York, NY
      Inner City Minorities and Hypertension
         Charles K. Francis, MD, New York, NY
      Insured Worksite Programs and Hypertension
         Michael H. Alderman, MD, Bronx, NY
      Effect of Managed Care on Hypertension Treatment
         Kent Thompson, Ernst and Young, Palo Alto, CA
      Discussion

5:00 PM to 7:00 PM
------------------
Theme I: ALTERED CELLULAR ION REGULATION IN HYPERTENSION
      Overview
         Abraham Aviv, MD, Newark, NJ
      Ion Transport and the Cytoskeleton in Hypertension:
      A Genetic Link
         Giuseppe Bianchi, MD, Milan, Italy
      Altered Cellular Signaling in an In Vitro Model of
      Human Essential Hypertension
         Winfried Siffert, MD, PhD, Essen, Germany
      Circulating Inhibitors of the Na+-pump; the Na+/Ca2+
      Exchange and Primary Hypertension
         Mordecai P. Blaustein, MD, Baltimore, MD
      The Links Between Cellular Ca2+ and the Na+/H+
      Antiport in the Pathophysiology of Essential Hypertension
         Abraham Aviv, MD, Newark, NJ
      Discussion
Theme II: DEBATES
      SHOULD DIHYRDOPYRIDINES BE USED FOR FIRST LINE TREATMENT?
         Pro: Murray Epstein, MD, Miami, FL
         Con: Curt D. Furberg, MD, PhD, Winston-Salem, NC
      Discussion
      DIURETICS:  THE QUESTIONS CONTINUE
         Pro: Ray W. Gifford, Jr, MD, Cleveland, OH
         Con: Norman M. Kaplan, MD, Dallas, TX
      Discussion
Theme III: HOW TO DELIVER CARE THAT WORKS
      Managed Care Perspective
      Compliance
         Martha N. Hill, PhD, RN, Baltimore, MD
      Enhancing Patient-Provider Communication
         Debra Roter, DrPH, Baltimore, MD
      Total Disease Management
         Theodore A. Maurer, HLS Corp., Little Falls, NJ
         Steven Zatz, MD, US Healthcare, Blue Bell, PA
         John M. Harris, Jr, MD, MBA, Blue Cross of California,
         Woodland Hills, CA
      Panel Discussion
      Pharmaceutical Perspective
         Louis M. Sherwood, MD, Medical & Scientific Affairs
         Human Health Division, Merck & Co., Inc., West Point, PA
         Marie-Caroline Sainpy, U.S. Pharmaceuticals Group, Pfizer
         Inc, New York, NY
         John Montgomery, Parke-Davis, Morris Plains, NJ
      Panel Discussion

--
John Mack
----------------------------------------------
John Mack       1-215-949-0490
Pharmaceutical Information Associates, Ltd.
2761 Trenton Road, Levittown, PA 19056 USA
Creators of PharmInfoNet, a Web site devoted to pharmaceutical information.
URL: http://www.***.com/




-----------------------------------------------